• 1. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropylamines

Compound Introduction: (2R)-2-(2,5-Difluorophenyl)propan-1-amine (CAS No. 2248186-52-7)

(2R)-2-(2,5-Difluorophenyl)propan-1-amine is a meticulously synthesized organic compound characterized by its unique structural and chemical properties. This compound, identified by the Chemical Abstracts Service Number (CAS No.) 2248186-52-7, has garnered significant attention in the field of pharmaceutical research due to its potential applications in drug development and molecular biology studies.

The molecular structure of (2R)-2-(2,5-Difluorophenyl)propan-1-amine consists of a propylamine backbone substituted with a 2,5-difluorophenyl group. This configuration imparts distinct electronic and steric properties, making it a valuable scaffold for designing novel bioactive molecules. The presence of fluorine atoms at the 2 and 5 positions enhances the compound's lipophilicity and metabolic stability, which are critical factors in pharmaceutical design.

In recent years, there has been a surge in research focused on fluorinated aromatic compounds due to their enhanced binding affinity and resistance to enzymatic degradation. Studies have demonstrated that the introduction of fluorine atoms can significantly modulate the pharmacokinetic profiles of drug candidates. For instance, the fluorine substitution in (2R)-2-(2,5-Difluorophenyl)propan-1-amine contributes to its prolonged half-life and improved bioavailability, making it an attractive candidate for further pharmacological exploration.

The stereochemistry of (2R)-2-(2,5-Difluorophenyl)propan-1-amine, specifically the (R) configuration at the chiral center, plays a pivotal role in determining its biological activity. Chiral drugs often exhibit different pharmacological effects depending on their stereoisomers, necessitating precise synthesis and characterization. Advanced spectroscopic techniques such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography have been employed to elucidate the structural details of this compound, ensuring high purity and enantiomeric excess.

Current research in medicinal chemistry has highlighted the importance of fluorinated amine derivatives in developing treatments for various diseases. The compound (2R)-2-(2,5-Difluorophenyl)propan-1-amine has shown promise in preclinical studies as a potential intermediate for synthesizing novel therapeutic agents. Its unique structural features make it a versatile building block for designing molecules targeting neurological disorders, infectious diseases, and cancer.

The synthesis of (2R)-2-(2,5-Difluorophenyl)propan-1-amine involves multi-step organic reactions that require precise control over reaction conditions to achieve high yields and purity. Techniques such as asymmetric hydrogenation and palladium-catalyzed cross-coupling reactions have been utilized to construct the desired stereocenter and aromatic ring system. These synthetic methodologies are critical for producing pharmaceutical-grade materials that meet stringent regulatory standards.

The pharmacological potential of (2R)-2-(2,5-Difluorophenyl)propan-1-amine has been explored in several in vitro and in vivo models. Preliminary studies suggest that this compound exhibits inhibitory activity against specific enzymes and receptors involved in disease pathways. For example, its interaction with targeted proteins may lead to the development of new antiviral or anticancer drugs. Further investigations are ongoing to elucidate its mechanism of action and optimize its pharmacological properties.

The role of computational chemistry in analyzing the properties of (2R)-2-(2,5-Difluorophenyl)propan-1-amine cannot be overstated. Molecular modeling techniques have been employed to predict binding affinities, metabolic stability, andADME (Absorption, Distribution, Metabolism, and Excretion) properties. These simulations provide valuable insights into how the compound behaves within biological systems, guiding experimental design and drug optimization efforts.

In conclusion, (2R)-2-(2,5-Difluorophenyl)propan-1-amine (CAS No. 2248186-52-7) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and promising biological activities. Ongoing research continues to uncover new applications for this compound, reinforcing its importance as a key intermediate in drug development. As scientific understanding progresses, it is anticipated that derivatives of this molecule will contribute to innovative therapeutic solutions across various medical disciplines.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)